AllianceBernstein
VIR icon

AllianceBernstein’s Vir Biotechnology VIR Stock Holding History

AllianceBernstein’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
135,990
+28,140
+26% +$268K ﹤0.01% 2301
2026
Q1 		$650K Sell
107,850
-1,770
-2% -$14.1K ﹤0.01% 2511
2025
Q4 		$661K Hold
109,620
– – ﹤0.01% 2527
2025
Q3 		$626K Hold
109,620
– – ﹤0.01% 2563
2025
Q2 		$552K Hold
109,620
– – ﹤0.01% 2581
2025
Q1 		$710K Hold
109,620
– – ﹤0.01% 2400
2024
Q4 		$805K Hold
109,620
– – ﹤0.01% 2426
2024
Q3 		$821K Hold
109,620
– – ﹤0.01% 2412
2024
Q2 		$976K Hold
109,620
– – ﹤0.01% 2313
2024
Q1 		$1.11M Sell
109,620
-2,671,429
-96% -$27.2M ﹤0.01% 2209
2023
Q4 		$28M Sell
2,781,049
-116,685
-4% -$1.07M 0.01% 753
2023
Q3 		$27.2M Buy
2,897,734
+146,018
+5% +$2.08M 0.01% 751
2023
Q2 		$67.5M Buy
2,751,716
+2,871
+0.1% +$72.1K 0.03% 491
2023
Q1 		$64M Buy
2,748,845
+394,986
+17% +$10.1M 0.03% 496
2022
Q4 		$59.6M Buy
2,353,859
+19,541
+0.8% +$479K 0.03% 523
2022
Q3 		$45M Sell
2,334,318
-466,219
-17% -$11.9M 0.02% 565
2022
Q2 		$71.3M Sell
2,800,537
-290,568
-9% -$6.78M 0.03% 460
2022
Q1 		$79.5M Buy
3,091,105
+470,352
+18% +$14M 0.03% 466
2021
Q4 		$110M Buy
2,620,753
+483,261
+23% +$18.9M 0.04% 422
2021
Q3 		$93M Buy
2,137,492
+16,466
+0.8% +$713K 0.04% 445
2021
Q2 		$100M Buy
2,121,026
+322,247
+18% +$14.7M 0.04% 433
2021
Q1 		$92.2M Sell
1,798,779
-1,168,027
-39% -$62.9M 0.04% 423
2020
Q4 		$79.5M Buy
2,966,806
+885,381
+43% +$28.8M 0.04% 445
2020
Q3 		$71.5M Buy
2,081,425
+142,553
+7% +$6.14M 0.04% 440
2020
Q2 		$79.4M Buy
1,938,872
+1,917,072
+8,794% +$64.3M 0.05% 390
2020
Q1 		$747K Buy
+21,800
New +$586K ﹤0.01% 2168

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AllianceBernstein's VIR Position: Q2 2026 in Review

AllianceBernstein increased its Vir Biotechnology (VIR) stake by 26% in Q2 2026, buying an estimated $268K and bringing the position to 135,990 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

AllianceBernstein first reported a position in VIR in Q1 2020 and has held it in 26 quarters since. The position peaked at $110M in Q4 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • AllianceBernstein held 135,990 shares of Vir Biotechnology worth $1.22M as of Q2 2026.
  • AllianceBernstein bought 28,140 Vir Biotechnology shares in Q2 2026, an estimated $268K.
  • Vir Biotechnology made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2301 holding.
  • AllianceBernstein first reported a position in Vir Biotechnology in Q1 2020 and has held it in 26 quarters since.
  • AllianceBernstein's Vir Biotechnology position peaked at $110M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.